Zileuton

5-Lipoxygenase Inhibitor

Key facts

Zileuton is an ofp drug in the 5-Lipoxygenase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1996. Its mechanism of action is classified as 5-Lipoxygenase Inhibitors. DrugCentral lists 11 molecular targets, including Alox5, Alox5 and ALOX5. Recorded indications include Allergic asthma, Asthma management and Non-allergic asthma.

• Approval status: ofp (first approved 1996 by the FDA).
• Drug class: 5-Lipoxygenase Inhibitor.
• Mechanism of action: 5-Lipoxygenase Inhibitors.
• Molecular targets: Alox5, Alox5, ALOX5 and ALOX15 (11 listed in DrugCentral).
• Indications: Allergic asthma, Asthma management and Non-allergic asthma.
• Molecular formula: C11H12N2O2S; molecular weight 236.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Allergic asthma
• Asthma management
• Non-allergic asthma

Contraindications (11)

• Anxiety
• Depressive disorder
• Disease of liver
• Dream disorder
• Feeling agitated
• Hallucinations
• Liver function tests abnormal
• Mood swings
• Nervousness
• Suicidal thoughts
• Tremors

Mechanism & targets

• Mechanism of action (MoA): 5-Lipoxygenase Inhibitors
• Established pharmacologic class: 5-Lipoxygenase Inhibitor

Molecular targets (11)

Target	Gene	Action	Activity
Arachidonate 5-lipoxygenase	Alox5	unknown	IC50 6.85
Arachidonate 5-lipoxygenase	Alox5	unknown	IC50 6.72
Arachidonate 5-lipoxygenase	ALOX5	inhibitor	IC50 6.52
Arachidonate 15-lipoxygenase	ALOX15	unknown	IC50 6.40
Leukotriene B4 receptor 1	LTB4R	unknown	IC50 6.38
Bifunctional epoxide hydrolase 2	EPHX2	unknown	IC50 6.23
Prostaglandin E synthase	PTGES	unknown	IC50 6.22
Leukotriene A-4 hydrolase	LTA4H	unknown	IC50 6.07
Cysteinyl leukotriene receptor 2	CYSLTR2	unknown	IC50 5.82
Arachidonate 5-lipoxygenase-activating protein	ALOX5AP	unknown	IC50 5.66
Protein-lysine 6-oxidase	LOX	unknown	IC50 5.46

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1996-12-09	FDA	—	CHIESI USA INC

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Asthma	65.3
Anaphylactic reaction	36.4
Drug ineffective for unapproved indication	32.3

Chemical structure

• Molecular formula: C₁₁H₁₂N₂O₂S
• Molecular weight: 236.29 g/mol
• CAS number: 111406-87-2
• InChIKey: MWLSOWXNZPKENC-UHFFFAOYSA-N
• PubChem CID: 60490

CC(N(O)C(N)=O)C1=CC2=C(S1)C=CC=C2

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Zileuton used for?

DrugCentral lists the following indications for Zileuton: Allergic asthma, Asthma management and Non-allergic asthma.

How does Zileuton work?

Zileuton is classified as 5-Lipoxygenase Inhibitors; its molecular targets in DrugCentral include Alox5, Alox5, ALOX5 (inhibitor) and ALOX15.

When was Zileuton first approved?

Zileuton was first approved by the FDA in 1996.

What drug class does Zileuton belong to?

Zileuton is in the 5-Lipoxygenase Inhibitor class.

What is the chemical formula of Zileuton?

Zileuton has the molecular formula C11H12N2O2S and a molecular weight of 236.29 g/mol.

Sources

• DrugCentral drug card 2862 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL93 — compound record and bioactivity
• PubChem CID 60490 — chemical identifiers
• DrugBank DB00744 — drug record
• FDA UNII V1L22WVE2S — substance identity
• DailyMed: FDA labels for Zileuton — current prescribing information (label search)
• UniProt P09917 (ALOX5) — target protein
• UniProt P16050 (ALOX15) — target protein
• UniProt Q15722 (LTB4R) — target protein
• UniProt P34913 (EPHX2) — target protein
• UniProt O14684 (PTGES) — target protein
• UniProt P09960 (LTA4H) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.